An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies

Bibliography

• Li J, Thompson TD, Miller JW, et al. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics 2008;121:e1470-7
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst 2008;100:1301-9
   PubMed Web of Science ®Google Scholar
• Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 2008;111:5515-23
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82
   PubMed Web of Science ®Google Scholar
• Alvarez JA, Scully RE, Miller TL, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 2007;19:23-31
   PubMed Web of Science ®Google Scholar
• Miller TL, Lipsitz SR, Lopez-Mitnik G, et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010;19:2013-22
   PubMed Web of Science ®Google Scholar
• Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58
   PubMed Web of Science ®Google Scholar
• Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010;304:172-9
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606
   PubMed Web of Science ®Google Scholar
• Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777-84
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145-53
   PubMed Web of Science ®Google Scholar
• Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25
   PubMed Web of Science ®Google Scholar
• Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 1996;97:818-21
   PubMed Web of Science ®Google Scholar
• Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-52
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010;24:320-34
   PubMed Web of Science ®Google Scholar
• Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41
   PubMed Web of Science ®Google Scholar
• Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19:191-6
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15
   PubMed Web of Science ®Google Scholar
• Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44:600-6
   PubMed Web of Science ®Google Scholar
• Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25:72-85
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-33
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-17
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042-9
   PubMed Web of Science ®Google Scholar
• Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003;16:1091-110
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Sanders SP, Goorin AM, et al. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433-7
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79
   PubMed Web of Science ®Google Scholar
• Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-50
   PubMed Web of Science ®Google Scholar
• Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 2011;32:342-53
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988;6:1321-7
   PubMed Web of Science ®Google Scholar
• Landy DC, Miller TL, Lipsitz SR, et al. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Cardiol 2012; doi:10.1007/s00246-012-0539-6; Epub ahead of print
   PubMedGoogle Scholar
• Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008;112:2789-95
   PubMed Web of Science ®Google Scholar
• Miranda CJ, Makui H, Soares RJ, et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 2003;102:2574-80
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Kutok J, et al. Impact of HFE mutations on cardiac status in survivors of childhood high-risk ALL: Dana-Farber Cancer Institute Childhood ALL 05-159. J Clin Oncol 2011;29(Suppl):abstract 9508
   Google Scholar
• Perego P, Corna E, De Cesare M, et al. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 2001;8:31-7
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-42
   PubMed Web of Science ®Google Scholar
• Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076-86
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980;65:128-35
   PubMed Web of Science ®Google Scholar
• Goormaghtigh E, Huart P, Praet M, et al. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 1990;35:247-57
   PubMed Web of Science ®Google Scholar
• Arai M, Yoguchi A, Takizawa T, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res 2000;86:8-14
   PubMed Web of Science ®Google Scholar
• Jeyaseelan R, Poizat C, Baker RK, et al. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 1997;272:22800-8
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Gerschenson M, et al. Impaired mitochondrial structure and function which is abrogated by dexrazoxane in doxorubicin-treated childhood ALL survivors. American Society of Clinical Oncology Annual Meeting, 2012
   Google Scholar
• Lebrecht D, Setzer B, Ketelsen UP, et al. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003;108:2423-9
   PubMed Web of Science ®Google Scholar
• Childs AC, Phaneuf SL, Dirks AJ, et al. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:bax ratio. Cancer Res 2002;62:4592-8
   PubMed Web of Science ®Google Scholar
• Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract 2011;2011:134679
   PubMedGoogle Scholar
• Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002;20:1677-82
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 2012;130:1003-11
   PubMed Web of Science ®Google Scholar
• Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788-856
   PubMed Web of Science ®Google Scholar
• Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;12:CD005006
   Google Scholar
• Goldin A, Venditti JM, Geran R. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review. Invest New Drugs 1985;3:3-21
   PubMed Web of Science ®Google Scholar
• Lahtinen R, Kuikka J, Nousiainen T, et al. Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 1991;46:301-5
   PubMed Web of Science ®Google Scholar
• Martoni A, Piana E, Guaraldi M, et al. Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology 1990;47:427-32
   PubMed Web of Science ®Google Scholar
• Anderlini P, Benjamin RS, Wong FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995;13:2827-34
   PubMed Web of Science ®Google Scholar
• Shenkenberg TD, Von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986;105:67-81
   PubMed Web of Science ®Google Scholar
• Pellicori P, Calicchia A, Lococo F, et al. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol. Congest Heart Fail 2012;18:217-21
   PubMedGoogle Scholar
• Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54(Suppl 4):15-21
   PubMed Web of Science ®Google Scholar
• Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711-16
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-33
   PubMed Web of Science ®Google Scholar
• Reynolds JG, Geretti E, Hendriks BS, et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012;262:1-10
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517-22
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010;11:950-61
   PubMed Web of Science ®Google Scholar
• Lipinczyk TM, Lipshultz SE. Cardioprotective effects of dexrazoxane in children with acute lymphoblastic leukemia treated with doxorubicin: an overview. Am J Oncol Rev 2005;4:103-16
   Google Scholar
• Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996;14:328-31
   PubMed Web of Science ®Google Scholar
• Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007;67:8839-46
   PubMed Web of Science ®Google Scholar
• Herman EK, Zhang A, Hiraragi H, Lipshultz SE. Gender is a factor that can impact the severity of doxorubicin (DXR) toxicity in spontaneously hypertensive rats (SHR). FASEB J 2008;22:719-16
   Google Scholar
• Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 2009;64:243-51
   PubMed Web of Science ®Google Scholar
• Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007;25:493-500
   PubMed Web of Science ®Google Scholar
• Barry EV, Vrooman LM, Dahlberg SE, et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008;26:1106-11
   PubMed Web of Science ®Google Scholar
• Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011;47:1373-9
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Orav EJ. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J Clin Oncol 2007;25:3179; author reply 3180
   PubMed Web of Science ®Google Scholar
• Hellmann K. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J Clin Oncol 2007;25:4689-90. author reply 4690-4681
   PubMed Web of Science ®Google Scholar
• Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005;131:561-78
   PubMed Web of Science ®Google Scholar
• Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L
   PubMed Web of Science ®Google Scholar
• Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 1999;18:269-74
   PubMed Web of Science ®Google Scholar
• Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 2001;138:505-11
   PubMed Web of Science ®Google Scholar
• Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988;48:3634-40
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer 1995;31A(Suppl 1):S8-13
   Google Scholar
• Dragojevic-Simic VM, Dobric SL, Bokonjic DR, et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 2004;15:169-78
   PubMed Web of Science ®Google Scholar
• Herman EH, Zhang J, Chadwick DP, Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000;45:329-34
   PubMed Web of Science ®Google Scholar
• Zimetbaum P, Eder H, Frishman W. Probucol: pharmacology and clinical application. J Clin Pharmacol 1990;30:3-9
   PubMed Web of Science ®Google Scholar
• Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-9
   PubMed Web of Science ®Google Scholar
• Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-15
   PubMed Web of Science ®Google Scholar
• Li T, Danelisen I, Bello-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 2000;46:523-30
   PubMed Web of Science ®Google Scholar
• De Flora S, Bennicelli C, Serra D, et al. Role of glutathione and N-acetylcysteine on the mutagenicity and carcinogenesis. CRC Press; Boca Raton, USA: 1989
   Google Scholar
• Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983;10:53-5
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995;16(Suppl F):38-42
   PubMedGoogle Scholar
• Matsui H, Morishima I, Numaguchi Y, et al. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999;65:1265-74
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37:837-46
   PubMed Web of Science ®Google Scholar
• Quiles JL, Huertas JR, Battino M, et al. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002;180:79-95
   PubMed Web of Science ®Google Scholar
• Ciaccio M, Tesoriere L, Pintaudi AM, et al. Vitamin A preserves the cytotoxic activity of adriamycin while counteracting its peroxidative effects in human leukemic cells in vitro. Biochem Mol Biol Int 1994;34:29-335
   Google Scholar
• Traber MG, Packer L. Vitamin E: beyond antioxidant function. Am J Clin Nutr 1995;62:1501S-9S
   PubMed Web of Science ®Google Scholar
• Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Yamagami T, Folkers K, Blomqvist CG. Deficiency of coenzyme Q10 in hypertensive rats and reduction of deficiency by treatment with coenzyme Q10. Biochem Biophys Res Commun 1974;58:743-8
   PubMed Web of Science ®Google Scholar
• Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 1993;192:241-5
   PubMed Web of Science ®Google Scholar
• Doba T, Burton GW, Ingold KU. Antioxidant and co-antioxidant activity of vitamin C. The effect of vitamin C, either alone or in the presence of vitamin E or a water-soluble vitamin E analogue, upon the peroxidation of aqueous multilamellar phospholipid liposomes. Biochim Biophys Acta 1985;835:298-303
   PubMed Web of Science ®Google Scholar
• Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 1991;54:1298S-301S
   Google Scholar
• Antunes LM, Takahashi CS. Protection and induction of chromosomal damage by vitamin C in human lymphocyte cultures. Teratog Carcinog Mutagen 1999;19:53-9
   PubMedGoogle Scholar
• Faber M, Coudray C, Hida H, et al. Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biol Trace Elem Res 1995;47:117-23
   PubMed Web of Science ®Google Scholar
• Matsuda A, Kimura M, Itokawa Y. Influence of selenium deficiency on the acute cardiotoxicity of adriamycin in rats. Biol Trace Elem Res 1997;57:157-67
   PubMedGoogle Scholar
• Van Vleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980;99:13-42
   PubMed Web of Science ®Google Scholar
• Van Vleet JF, Greenwood L, Ferrans VJ, Rebar AH. Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res 1978;39:997-1010
   PubMedGoogle Scholar
• Haq MM, Legha SS, Choksi J, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985;56:1361-5
   PubMed Web of Science ®Google Scholar
• Redfield MM, Gersh BJ, Bailey KR, Rodeheffer RJ. Natural history of incidentally discovered, asymptomatic idiopathic dilated cardiomyopathy. Am J Cardiol 1994;74:737-9
   PubMedGoogle Scholar
• van Dalen EC, Caron HN, Kremer LC. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer 2007;43:1134-40
   PubMed Web of Science ®Google Scholar
• Levitt G, Anazodo A, Burch M, Bunch K. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer 2009;45:3027-34
   PubMed Web of Science ®Google Scholar
• Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997;75:55-7
   PubMed Web of Science ®Google Scholar
• Kettunen R, Huikuri HV, Oikarinen A, Takkunen JT. Methotrexate-linked ventricular arrhythmias. Acta Derm Venereol 1995;75:391-2
   PubMed Web of Science ®Google Scholar
• Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-18
   PubMed Web of Science ®Google Scholar
• Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin 2001;17:483-502
   PubMedGoogle Scholar